Pyxis Oncology reports 39% confirmed response rate for MICVO in Phase 1 head and neck cancer trial
- Pyxis Oncology reported updated Phase 1 results showing durable responses to MICVO in previously treated recurrent or metastatic head and neck cancer.
- Clinical activity was consistent across patient subgroups, with a manageable safety profile.
- The findings support plans to initiate the global Phase 3 Headliner trial in mid-2027.
- Results will be presented November 19, 2026, at the EORTC-NCI-AACR Symposium in Barcelona.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611181801PRIMZONEFULLFEED9880646) on November 18, 2026, and is solely responsible for the information contained therein.